Chronic Lymphocytic Leukemia

332

Pipeline Programs↗

112

Active Trials↗

106

Companies Involved↗

Chronic Lymphocytic Leukemia is a highly competitive landscape with 332 programs across 106 companies. The most active players are Vincerx Pharma, Inc., Institut de Recherches Internationales Servier, Boehringer Ingelheim. 25 therapies are approved with 28 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

89/100

Pipeline Velocity

41/100

Mech. Concentration

4/100

Completion Rate

71/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Vincerx Pharma, Inc.

2 programs

Institut de Recherches Internationales Servier

2 programs

Boehringer Ingelheim

2 programs

Acerta Pharma BV

1 program

XEME Biopharma Inc.

1 program

Catapult Therapeutics

1 program

Pipeline

Programs by Phase

Preclinical19

Alemtuzumab

Genzyme, a Sanofi Company

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Lamivudine

Glaxo Dba Glaxosmithkline

Ofatumumab

Novartis

Fludarabine Phosphate

Sanofi

Phase 196

Aldesleukin

Iovance Biotherapeutics, Inc.

Polatuzumab Vedotin

Roche

Anakinra

Swedish Orphan Biovitrum

Blinatumomab

Amgen

Nivolumab

Bristol-Myers Squibb

Phase 2164

Belimumab

Glaxo Dba Glaxosmithkline

Eltrombopag

GSK

Epcoritamab

Genmab

Cediranib Maleate

National Cancer Institute (NCI)

Tafasitamab

Incyte

Phase 328

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Alvocidib

Sumitomo Pharma America, Inc.

Zanubrutinib

BeOne Medicines

Obinutuzumab

Roche

Approved25

Hydroxychloroquine

Alnylam Pharmaceuticals

Bupropion

Glaxo Dba Glaxosmithkline

Ciprofloxacin

Bayer

Fludarabine

Sanofi

Adenosine

Astellas

Analysis

Modality Breakdown

79%

Small molecule

266 of 337 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 337 classified programs, each share of the total. Modality classified for 99% of 368 pipeline programs.

Analysis

Trial Status

614

clinical trials

Completed337 · 55%

Terminated96 · 16%

Active, not recruiting56 · 9%

Recruiting48 · 8%

Withdrawn37 · 6%

Unknown status28 · 5%

Other12 · 2%

Clinical Trials

Trial Activity

614 trials

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Recruiting·—·Phase 1/2·NCT04771507·50 enrolled

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting·—·Phase 1/2·NCT06644183·64 enrolled

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Recruiting·PPaolo Caimi, MD·Phase 1·NCT06916767·18 enrolled

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT03986034·75 enrolled

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Recruiting·—·Phase 2·NCT05417165·80 enrolled

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Recruiting·CCatapult Therapeutics·Phase 1·NCT04704323·18 enrolled

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT04895436·75 enrolled

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Recruiting·—·Phase 2·NCT07218510·33 enrolled

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04941716·20 enrolled

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Recruiting· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT05645107·386 enrolled

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05536349·60 enrolled

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04505254·60 enrolled

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Recruiting·UUniversity of Utah·Phase 2·NCT04844528·86 enrolled

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT05943496·27 enrolled

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06839053·20 enrolled

Page 1 of 41

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)